Issue 1078: September 19, 2013
Please note: A clarification has been published for
Q&A #4 in this issue of "Ask
Questions and Answers
Q: What influenza vaccine products will be available during the 2013–14 influenza season?
A: Seven manufacturers now produce influenza vaccine for the U.S. market through different technologies (e.g., egg-based, cell culture-based, and recombinant hemagglutinin vaccines). The seven manufacturers and the products they have available for the upcoming season are listed below.
Q: What are the differences in trivalent and quadrivalent influenza vaccines?
A: Most of the influenza vaccine offered for the 2013–2014 season will be trivalent (three components), containing two A viruses and one of the B viruses. The 2013–2014 trivalent influenza vaccine is made from the following three viruses:
A limited quantity of seasonal influenza vaccine will be quadrivalent (four components), containing two A viruses and two B viruses. The quadrivalent vaccines will contain the three viruses listed above, plus a B/Brisbane/60/2008-like virus.
Q: If quadrivalent vaccine includes one additional strain, why isn’t it preferred for use over trivalent vaccines in ACIP’s 2013–14 influenza recommendations?
A: Even though both influenza B viruses are likely to cause disease during an influenza season, for trivalent vaccine, experts had to choose between the two very different B viruses to pair with the two A viruses. The quadrivalent vaccine that will be available for the 2013–14 season includes both B viruses. However, while quadrivalent vaccines may eventually replace trivalent vaccines, it is anticipated that during the coming season only a limited quantity of quadrivalent vaccine will be available. Consequently, ACIP does not express a preference for use of one type of influenza vaccine over another type (i.e., live over inactivated, or quadrivalent over trivalent) for persons for whom more than one type of vaccine is indicated and available.
Q: I heard there was a new influenza vaccine that can be given to people with severe egg allergies. Is that true?
A: If someone has a severe allergy to eggs with symptoms suggestive of anaphylaxis and the patient is age 18 through 49 years, then the provider can consider using Flublok, the recombinant influenza vaccine that is egg-free. Unlike current production methods for other available seasonal influenza vaccines, production of Flublok does not use the whole influenza virus or chicken eggs in its manufacturing process. If Flublok is not available or the patient is not age-eligible, then the patient should be referred to a provider experienced in managing allergy.
Q: How many doses of vaccine are recommended for children younger than 9 years who are receiving influenza vaccine for the first time?
A: In settings where adequate vaccination history from prior to the 2010–2011 season is unavailable, children 6 months through 8 years of age need only 1 dose of vaccine in 2013–2014 if they received a total of 2 or more doses of seasonal vaccine since July 1, 2010. Children who did not receive a total of 2 or more doses of seasonal vaccine since July 1, 2010, require 2 doses in 2013–2014. In settings where adequate vaccination history from prior to the 2010–2011 season is available, an alternate approach may be used. This is the alternate approach: If a child age 6 months through 8 years is known to have received at least 2 doses of seasonal influenza vaccine during any prior season, and at least 1 dose of a 2009 (H1N1)-containing vaccine—i.e., either 2010–2011, 2011–2012, or 2012–2013 seasonal vaccine or the monovalent (H1N1) 2009 vaccine—then the child needs only 1 dose for 2013–2014. Otherwise the child needs 2 doses for the 2013–2014 season.
Q: Can a child who needs 2 doses of influenza receive 1 dose of quadrivalent vaccine and 1 dose of trivalent vaccine?
A: Yes. You can give these two vaccines, as long as the 2 doses are appropriately spaced.
Q: Does ACIP recommend one influenza product over another for pregnant women?
A: Pregnant women can receive any of the inactivated vaccines. They should not be given the live quadrivalent attenuated influenza vaccine (FluMist, MedImmune, LAIV4).
Q: Why is a higher dose influenza vaccine (Fluzone High-Dose) available for adults 65 and older?
A: Aging decreases the body’s ability to develop a good immune response after getting influenza vaccine, which places older people at greater risk of severe illness from influenza. A higher dose of antigen in the vaccine should give older people a better immune response and therefore provide better protection against influenza. Data from clinical trials comparing Fluzone to Fluzone High-Dose among people age 65 and older indicate that a stronger immune response (i.e., higher antibody levels) occurs after vaccination with Fluzone High-Dose. Whether the improved immune response leads to greater protection against influenza disease after vaccination is not yet known. A study designed to determine how effective Fluzone High-Dose is in preventing illness from influenza, when compared with standard-dose Fluzone, is expected to be completed in 2014–2015.
Q: If a patient is undergoing treatment for cancer, is it safe to vaccinate her or him against influenza?
A: People with cancer need to be protected from influenza, and they can and should receive inactivated influenza vaccine (not LAIV) even if they are immunosuppressed. Cancer patients and survivors are at higher risk for complications from flu, including hospitalization and death.
Q: If a woman received Tdap in early pregnancy, should she get it again in the third trimester?
A: No, it is not recommended to give another dose of Tdap in such cases. Optimal timing for Tdap administration is between 27 and 36 weeks’ gestation because of transplacental antibody kinetics.
Q: Each time there is a pregnancy in the family, should fathers and other family members receive a Tdap booster to ensure adequate protection and boost the cocoon effect to protect the newborn from pertussis?
A: At this time, ACIP does not recommend additional doses of Tdap for fathers or other family members/caregivers. The multiple Tdap recommendation to optimize immunity for the infant applies only to the pregnant woman.
Q: A pertussis outbreak is occurring in our town, with many cases happening in the schools. Is there a recommendation for boosting middle and high-school students with an additional dose of Tdap during an outbreak if students have already had 1 dose?
A: Currently, ACIP recommends only 1 lifetime dose of Tdap for everyone except pregnant women.
Q: Currently, ACIP recommends pneumococcal polysaccharide (PPSV23) for smokers age 19–64 years. Should we also vaccinate 16-year-olds who smoke?
A: No. Currently no data exist to indicate that people younger than 19 are at increased risk of neumococcal disease.
Q: Rather than giving pneumococcal conjugate vaccine (PCV13) first and waiting 8 weeks to give PPSV as recommended for an immunocompromised child (2 years+) or adult patient, we inadvertently gave both vaccines at the same visit. We are looking for guidance.
A: When these two vaccines are given simultaneously, each probably affects the other detrimentally. The risk of diminished responsiveness (which is “caused” by PPSV23, not PCV13) means that you should count the PPSV23 dose as valid for adults, and repeat the PCV13 dose 1 year after the PPSV23 dose was administered. You should count the PPSV23 dose as valid for children, and repeat the PCV13 dose 8 weeks after the PPSV23 dose was administered and complete the series as age appropriate.
Q: What is the latest on rotavirus vaccination and intussusception?
A: Some, but not all, studies suggest that RotaTeq and Rotarix vaccines may possibly cause a small increase in the risk of intussusception. It is possible that an estimated one to three U.S. infants out of 100,000 might develop intussusception within 7 days of getting their first dose of rotavirus vaccine. That means 40 to 120 vaccinated U.S. infants might develop intussusception each year.
Q: Why did Merck discontinue the registry for collecting reports of pregnant women who inadvertently received its HPV vaccine (Gardasil) during pregnancy?
A: Because HPV vaccine is not recommended for use during pregnancy, Merck facilitated a registry to document outcomes when its HPV vaccine (Gardasil) was inadvertently administered to pregnant women. This registry was ongoing for more than 6 years (June 2006 –April 2013), and Merck has fulfilled its FDA obligation to facilitate it. But more importantly, the data from the registry are reassuring with respect to safety after pregnancy exposures. Review of the data collected during the first 5 years of the registry does not support a causal relationship between HPV vaccine and birth defects.
Q: Why does CDC include 2D barcodes on VISs now?
A: As part of a modernization initiative, CDC began adding barcodes to VISs in April 2012. The addition of the barcode is intended primarily to help immunization providers save time by allowing them to scan certain required information about the VIS (e.g., the name and edition date of the VIS) into an electronic medical record, immunization information system, or other electronic database. Scanning the barcode instead of manually recording the information is optional.
Q: It seems CDC is changing the format of VISs. Do we have to throw our old supply away and use the new ones?
A: Not necessarily. CDC is in the process of re-releasing all VISs in a slightly modified format. The modified VISs have a consistent look and use consistent language in the sections common to all VISs. Modified VISs will not necessarily be new, but may simply be redesigned versions of existing VISs and have the same edition dates as existing VISs. Providers do not need to discard their existing VIS stocks when nothing but the VIS format has been changed. CDC posts information on its website to alert healthcare providers when the older version of a VIS should not be used. This information is available on CDC’s web section titled What's New with VISs.
How to submit a question to Ask the Experts
IAC works with CDC to compile new Ask the Experts Q&As for our publications based on commonly asked questions. We also consider the need to provide information about new vaccines and recommendations. Most of the questions are thus a composite of several inquiries.
IZ Express is supported in part by Grant No. 1NH23IP922654 from CDC’s National Center for Immunization and Respiratory Diseases. Its contents are solely the responsibility of Immunize.org and do not necessarily represent the official views of CDC.IZ Express DisclaimerISSN 2771-8085
Editor-in-ChiefKelly L. Moore, MD, MPH
Managing EditorJohn D. Grabenstein, RPh, PhD
Associate EditorSharon G. Humiston, MD, MPH
Writer/Publication CoordinatorTaryn Chapman, MS
Courtnay Londo, MA
Style and Copy EditorMarian Deegan, JD
Web Edition ManagersArkady Shakhnovich
Contributing WriterLaurel H. Wood, MPA
Technical ReviewerKayla Ohlde